USPTO Leadership Vacancies Raise Questions About Squires’ Management and Priorities

Although U.S. Patent and Trademark Office (USPTO) Director John Squires just officially announced last week that former counsel to Judge Pauline Newman, Greg Dolin, will be the new Deputy General Counsel and Solicitor, following the appointment of John Duffy as General Counsel last month, nearly 14 months after Squires became Director on September 22, 2025, the agency continues to operate with significant leadership vacancies, temporary appointments, and weakened oversight.

Other Barks & Bites for Friday, November 13: Tech Giants Oppose Indonesia AI Copyright Bill; Netlist Fails Appeal of PTAB’s Motivation to Combine Ruling; and CJEU AG Says General Court Erred in Reversing €1.5 Billion Google Fine

This Week in Other Barks & Bites: the Federal Circuit rules that the inoperability of a prior art reference in combination with another does not extinguish the motivation to combine those references; the U.S. Trade Representative extends its Special 301 investigation into Vietnam’s IP practices through next February; and more.

Squires Returns Merits-Based Institution to PTAB Judges

On Tuesday, a memorandum issued to administrative patent judges (APJs) of the Patent Trial and Appeal Board (PTAB) by U.S. Patent and Trademark Office Director John Squires and USPTO’s General Counsel John Duffy announced that effective November 16, 2026, Director Squires would be relinquishing direct oversight on merits-based PTAB institution decisions to PTAB panels. The decision to return institution decisions back to the PTAB panels themselves has been in the works for several months, as was first reported by IPWatchdog in September. Giving PTAB panels the authority to decide which cases to institute comes just more than one-year after Squires centralized the decision-making power in the Director’s Office.

Understanding the Three Accrual Standards Applied by Courts for Trade Secret Misappropriation

Several recent federal appellate and district court decisions underscore that companies must promptly investigate and act on suspected trade secret theft. Delay can cost a trade secret owner an otherwise meritorious claim. The risk is compounded by uncertainty over when the Defend Trade Secrets Act’s (DTSA) three-year limitations period begins.

The ‘Halo Product’ Dividend

On October 15, 2026, a TESLA ROADSTER hung upside down, flipped into the air, and briefly hovered. Powered fans supplied suction for inverted travel. Cold-gas thrusters drawing on SPACEX technology controlled the airborne maneuver. The engineering question was how to make a car fly. The commercial question is what else that car could sell.

America’s Technology-Neutral Patent System Is a Competitive Advantage: Congress Should Protect It

Congress may soon abandon a principle that has guided the U.S. legal system for generations: the ability to obtain and enforce patent rights should not depend on the type of technology being invented. Straying from this core tenet risks weakening a key competitive advantage of the American innovation economy.

ChromaDex: Being Unsuccessful is Not ‘Exceptional’ Conduct

We live and practice in a time when it may seem to some patent litigators that it would border on malpractice to not move for attorney fees after any case is won. You don’t ask, you don’t get, right? What do we have to lose? The recent U.S. Court of Appeals for the Federal Circuit decision in Chromadex v. Elysium Health serves as a helpful reminder of the seemingly obvious notion that not all patent cases we win (or, for that matter, lose) are “exceptional.” And it suggests that overreaching in seeking fees may itself come with some costs.

Subscribe to IPWatchdog

This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.

Get Email Updates